Clinical trials targeting Gln metabolism have also been initiated, employing Gln antagonists and oral GLS inhibitors, to explore a new therapeutic approach for NSCLC with LKB1 inactivation or KEAP1 inactivation/NFE2L2 alteration (127, 128) (Table 1). This evidence concerns the gene GLS and non-small cell lung carcinoma.